慢性肾脏病患者心力衰竭的评估和管理。

IF 5.4 3区 材料科学 Q2 CHEMISTRY, PHYSICAL
ACS Applied Energy Materials Pub Date : 2024-03-01 Epub Date: 2023-09-20 DOI:10.1007/s10741-023-10346-x
Andrea Igoren Guaricci, Francesca Sturdà, Roberto Russo, Paolo Basile, Andrea Baggiano, Saima Mushtaq, Laura Fusini, Fabio Fazzari, Fulvio Bertandino, Francesco Monitillo, Maria Cristina Carella, Marco Simonini, Gianluca Pontone, Marco Matteo Ciccone, Giuseppe Grandaliano, Giuseppe Vezzoli, Francesco Pesce
{"title":"慢性肾脏病患者心力衰竭的评估和管理。","authors":"Andrea Igoren Guaricci, Francesca Sturdà, Roberto Russo, Paolo Basile, Andrea Baggiano, Saima Mushtaq, Laura Fusini, Fabio Fazzari, Fulvio Bertandino, Francesco Monitillo, Maria Cristina Carella, Marco Simonini, Gianluca Pontone, Marco Matteo Ciccone, Giuseppe Grandaliano, Giuseppe Vezzoli, Francesco Pesce","doi":"10.1007/s10741-023-10346-x","DOIUrl":null,"url":null,"abstract":"<p><p>Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values ​​of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10942934/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessment and management of heart failure in patients with chronic kidney disease.\",\"authors\":\"Andrea Igoren Guaricci, Francesca Sturdà, Roberto Russo, Paolo Basile, Andrea Baggiano, Saima Mushtaq, Laura Fusini, Fabio Fazzari, Fulvio Bertandino, Francesco Monitillo, Maria Cristina Carella, Marco Simonini, Gianluca Pontone, Marco Matteo Ciccone, Giuseppe Grandaliano, Giuseppe Vezzoli, Francesco Pesce\",\"doi\":\"10.1007/s10741-023-10346-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values ​​of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.</p>\",\"PeriodicalId\":4,\"journal\":{\"name\":\"ACS Applied Energy Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10942934/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Energy Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10741-023-10346-x\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, PHYSICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10741-023-10346-x","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}
引用次数: 0

摘要

心力衰竭(HF)和慢性肾脏病(CKD)是普通人群中发病率较高的两种病理状况。当它们共存于同一患者中时,会观察到它们之间的严格相互作用,因此受影响的患者需要临床多学科和个性化的管理。HF和CKD的诊断依赖于患者的体征和症状,但需要一些额外的工具,如基于血液的生物标志物和成像技术,来澄清和区分这些疾病的主要特征。由于推荐的新药物提高了HF患者的生存率,这对医生管理多种疾病患者,尤其是CKD患者提出了越来越大的挑战。然而,在HF和CKD患者中安全使用这些药物往往具有挑战性。了解哪些价值观​​对于肌酸酐或肾脏清除率,每种药物都是基本的。通过这篇综述,我们试图深入了解这一庞大而复杂的主题,以便对HF和CKD的诊断评估和治疗管理有更清晰的想法和更准确的参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Assessment and management of heart failure in patients with chronic kidney disease.

Assessment and management of heart failure in patients with chronic kidney disease.

Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values ​​of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Applied Energy Materials
ACS Applied Energy Materials Materials Science-Materials Chemistry
CiteScore
10.30
自引率
6.20%
发文量
1368
期刊介绍: ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信